BioCentury
ARTICLE | Top Story

EC approves Forxiga

November 15, 2012 12:46 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) said the European Commission approved Forxiga dapagliflozin to treat Type II diabetes. The partners said the approval is the first for a sodium-glucose cotransporter 2 (SGLT2) inhibitor for diabetes. Bristol-Myers said the timing of the drug's launch will depend on pricing negotiations in each country, adding that it is "too early to discuss specific details around pricing." ...